… FDA-approved for treatment of femoropopliteal lesions: the … treatment of de novo and
restenotic lesions, only the Lutonix, and IN.PACT Admiral balloons are approved for the treatment of …

… treatment of CFA atherosclerosis. Both modalities showed favorable outcomes in the treatment
of superficial femoral (SFA) … SFA lesions did not differ significantly between the 2 groups. …

… provide additional evidence that DCB is a viable treatment option for complex lesion/patient
cohorts. Previously, we reported a superior treatment effect of DCB in patients with diabetes …

… PACT SFA trial included 331 patients randomized to treatment with DCB (n = 220) … treatment
groups were well matched at baseline with similar demographics, comorbidities, and lesion …

… Antirestenotic drug-eluting technologies are currently dominating the treatment of femoropopliteal
… PTA for the treatment of atherosclerotic lesions in the SFA and/or PPA. Presented at …

… In our study, the target lesion was limited to the proximal SFA … Newer therapies (DA with
antirestenotic therapy and next-… improve the patency of FP lesions in the era of newer therapies. …

… Therefore, a treatment combination of debulking procedure using atherectomy plus
antirestenotic therapy using DCB seems to be promising to treat complex lesions. …

… of longer lesion lengths that are at a higher risk of treatment failure, the 2.4% target lesion
revascularization rate experienced in this trial is the lowest reported for an SFA device trial at …

… dissections in complex femoropopliteal lesions. DA might be a treatment option that can …
In the current meta-analysis, the proportion of patients with severe calcified lesions was 53…

… Over the past few years, the optimal treatment strategy for SFA lesions has been the subject
of investigation in numerous trials. The use of antirestenotic technology, either DCBs or drug-…